Big Pharma Has a Case of Merger Mania

**Tyler Crowe** (0:03)
Big Pharma is in a buying mood today on Motley Fool Hidden Gems Investing.
Welcome to Motley Fool Hidden Gems Investing. I'm your host, Tyler Crowe, and today I'm joined by longtime Fool contributors, Lou Whiteman and Mark Frankel. Now, it's Tuesday, I know the markets, it's down quite a bit, I think the NASDAQ's down about 2% as we are taping, but hey, you know what? Volatile times, markets are gonna market. Today, we're gonna dive into the pharmaceutical industry, and specifically, the seemingly large wave of M&A that we've seen in recent months. We're also gonna hit some mailbag questions specific to the pharmaceutical industry and kind of look at some of the companies in this industry that we think are doing incredibly well. Now, at first, I thought this was some weird coincidence of seeing several deal announcements in the deal section of the Wall Street Journal recently, but so far, 2026 has been a banner year for M&A in the pharmaceutical industry. Here's a fascinating stat, guys, on this wave.
So far this year, there have been more deals of $1 billion and more than all of 2025 Now, I'm sure there's lots of reasons we could go into a lot of them, but for each of you guys, what are some of the things that you're seeing that's driving this seemingly massive wave of consolidation, Lou?

**Lou Whiteman** (1:24)
Yeah. So there's always a lot of reasons, as you say, but I do think there are a lot of trends just that are converging right now to fuel this consolidation. First, we have a looming patent cliff kind of all over the industry, pharmaceutical patents last 20 years. But because most of that time, usually more than half of that time is pre-revenue, the drug development stage, there's only really a short window for these companies to profit off of their creations. And as soon as it goes off patent, which means people can compete with you on this drug, you tend to see the revenue just drop, you know, orders of magnitude. There's an estimated $300 billion in annual revenue coming off patent in the next few years. That's prompting a lot of companies to either find bigger partners or if you're big enough, find new revenue streams, hence the M&A. I just, I mean, look at Eli Lilly. They're a GLP-1 leader. They have a great portfolio. They are throwing all of the cash they're making into GLP-1s into a ton of deals, just trying to diversify their portfolio. Nature of biotech and pharmaceuticals is a lot of these won't work out, but you have a, if you cast your net wide enough, if you get good candidates, you might have the next big thing.
Add-in factors like regulatory pricing pressure, some interesting breakthroughs in areas like oncology and cardiology.
This is an attractive market for both buyers and sellers, and I think we're seeing it play out.

**Matt Frankel** (2:46)
You're right, Tyler. It has been a very active year for consolidation. Just to add a little bit of context to that, we've already seen 32 separate deals worth a billion dollars or more for a total deal value of $123 billion. That's significant because if this continues, it would be the strongest year for M&A in the space since 2019
Which was the strongest year ever. So we're on pace for not quite a record year, but we're getting there. And Lou mentioned that patent expiration is a big part of this. Almost 70 drugs that each generate over a billion dollars of revenue have their patents expiring within the next couple of years. So if you're not familiar, when their exclusivity period ends, it's not just that the revenue falls off a cliff, it really falls off a cliff. It could drop 80 to 90% overnight.
Many companies are scrambling not only to replace the revenue, but the profits these are generating because generally the patent-protected drugs are the highest margin part of these companies' balance sheet. So I mean, one interesting observation is as we mentioned, these are kind of not giant acquisitions. There's been a shift to bolt-on acquisitions from large mergers, focusing on assets that are saying late stage trials that could be integrated quickly into an established platform. That's one of the Eli Lilly acquisitions we just saw. Merck is another example. It's losing its patent protection for Keytruda, the cancer blockbuster cancer drug, and it's made three major acquisitions in the last 10 months alone. So you're seeing a lot of this from certain companies.

**Tyler Crowe** (4:12)
Yeah, and it's not just them. I mean, part of the reason I specifically saw this, it was in a matter of a couple of weeks, I saw like AbbVie buying immunology company for about 10 billion. GlaxoSmithKline was doing a $10 billion acquisition, and then Roche was even licensing drugs from other people. Mentioning Eli Lilly and Merck as well, it seems like everyone is incredibly active at this time, especially in the portfolio of developing drugs, and that's what I want to dig into a little bit deeper here, and it's the regulatory part because it does look like there has been some significant changes, at least in attitude in the FDA in recent months.